Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Farrukh T. Awan, November McGarvey, Abraham Lee, Ken Imanak, Simran K. Tiwana, Sean Garrison, Masoom Priyadarshini

Blood (2023) 142 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2023-178048

Published: 2023

Journal Articles

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Farrukh T. Awan, Gaurav A. Deshpande, Trong Kim Le, Sean Garrison, Simran K. Tiwana, Masoom Priyadarshini

Blood (2022) 140 (Supplement 1): 7028–7029.

https://doi.org/10.1182/blood-2022-159195

Published: 2022